Literature Analysis: Selective Degradation of Phosphorylated p38 MAPK (Tyr182) as a Novel Strategy for Alzheimer's Disease Therapy Literature Information
Literature Analysis: Selective Degradation of Phosphorylated p38 MAPK (Tyr182) as a Novel Strategy for Alzheimer's Disease Therapy
Literature Information
Title: How to treat Alzheimer's disease by selectively degrading phosphorylated p38 MAPK (Tyr182)
Core Theme: Targeted degradation of phosphorylated p38 MAPK (Tyr182) via PROTAC technology for Alzheimer's disease intervention, and application of phosphorylation‑specific antibodies in mechanistic validation and drug development
Research Background
Alzheimer's disease (AD) is characterized by β‑amyloid plaque deposition, neurofibrillary tangles, and chronic neuroinflammation. Phosphorylated p38 MAPK (p‑p38, Tyr182) is highly activated in AD brains, driving neuroinflammation, synaptic dysfunction, Aβ accumulation, and tau hyperphosphorylation. Traditional small‑molecule kinase inhibitors suffer from poor selectivity, off‑target effects, and disruption of physiological p38 functions. Proteolysis‑Targeting Chimera (PROTAC) technology offers a revolutionary approach to specifically degrade pathological p‑p38 while preserving native p38, enabling safer and more effective AD therapy.
Research Approach
This study establishes a conformation‑selective PROTAC strategy:
- Identify conformation‑specific ligands that exclusively recognize phosphorylated p38 MAPK (Tyr182)
- Construct p‑p38‑selective PROTAC molecules linked to E3 ligase ligands
- Validate selective degradation of p‑p38 without affecting total p38 in vitro
- Evaluate in vivo efficacy via intranasal administration in AD mouse models
- Assess pathological improvements and cognitive function recovery
- Use phosphorylation‑specific antibodies for target validation and pharmacodynamic evaluation
Research Outcomes
- p‑p38 (Tyr182) as a key driver of AD pathogenesis
Phosphorylation at Thr180/Tyr182 activates p38 MAPK, triggering NF‑κB‑mediated neuroinflammation, synaptic damage, and accelerated Aβ and tau pathology.
- Superiority of PROTAC over conventional kinase inhibitors
PROTAC achieves catalytic, long‑lasting, and highly selective degradation of pathological p‑p38, avoiding off‑target effects and preserving physiological p38 activity.
- Design and validation of selective p‑p38‑degrading PROTACs
Conformation‑selective ligands distinguish phosphorylated p38 from inactive p38. The optimized PROTAC compound induces CRBN‑dependent, proteasome‑mediated degradation specifically of p‑p38.
- In vivo efficacy in AD models
Intranasal delivery effectively penetrates the blood–brain barrier and clears p‑p38 in the cortex and hippocampus. Treatment reduces neuroinflammation, Aβ plaque load, and synaptic damage, significantly restoring spatial learning and memory.
- Antibody‑enabled validation
Phospho‑specific p38 (Tyr182) antibodies are essential for verifying selective degradation, quantifying pharmacodynamic effects, and supporting translational biomarker development.
Product Empowerment
ANT BIO PTE. LTD. provides the Phospho‑p38 MAPK (Tyr182) Recombinant Rabbit Monoclonal Antibody (S‑617‑138, Cat. No. S0B0897) under its Starter product line. This site‑specific antibody enables highly selective detection of dual‑phosphorylated p38 MAPK (Thr180/Tyr182), serving as a gold‑standard tool for AD research, PROTAC drug development, and signaling pathway analysis.
Key Roles in This Research:
- Specific detection of activated p‑p38 in brain tissues and cell models
- Quantitative validation of PROTAC‑mediated selective p‑p38 degradation
- Pharmacodynamic evaluation of drug efficacy in preclinical studies
- Immunofluorescence imaging of spatial p‑p38 distribution in the nervous system
- Biomarker development for AD diagnosis and treatment monitoring
Core Product Advantages
表格
|
Core Product Advantages |
|
High Phosphorylation Site Specificity: Precisely recognizes dual phosphorylation at Thr180 and Tyr182, the definitive marker of full p38 MAPK activation; no cross‑reactivity with non‑phosphorylated p38 or other MAPK family members. |
|
Excellent Stability & Batch‑to‑Batch Consistency: Recombinant production ensures robust stability and minimal inter‑batch variation, supporting reliable and reproducible results for long‑term studies. |
|
Broad Platform Compatibility: Validated for WB, IF, flow cytometry, and tissue staining; adaptable to diverse neuroscience and cell signaling research scenarios. |
Key Application Scenarios
表格
|
Key Application Scenarios |
|
Neuroinflammation & AD Research: Detect p38 activation in neurodegenerative models, evaluate anti‑inflammatory and neuroprotective drug effects. |
|
Cellular Stress Response Analysis: Monitor p38 phosphorylation under oxidative stress, ultraviolet radiation, osmotic stress, and heat shock. |
|
Inflammatory & Immune Regulation: Study p38‑mediated cytokine production (TNF‑α, IL‑6) in macrophages and immune cells. |
|
Cell Fate & Signaling Research: Explore p38 activity in apoptosis, autophagy, differentiation, and tumor drug resistance. |
|
PROTAC & Targeted Drug Development: Validate selective protein degradation and quantify pharmacodynamic responses. |
Brand Mission
ANT BIO PTE. LTD. is a leading provider of life science reagents, offering antibodies, recombinant proteins, assay kits, and general laboratory reagents. We operate three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering integrated solutions for neuroscience, oncology, immunology, and drug discovery. We are committed to supplying high‑quality, consistent, and innovative reagents to accelerate mechanistic research, therapeutic development, and progress in precision medicine.
Related Product List
表格
|
Product Name |
Catalog No. |
Applications |
|
Phospho‑p38 MAPK (Tyr182) Recombinant Rabbit mAb (S‑617‑138) |
S0B0897 |
WB, IF, FACS, tissue phosphorylation analysis |
|
Total p38 MAPK Antibody |
Starter series |
Control for total vs. phosphorylated p38 comparison |
|
MAPK Signaling Pathway Antibody Panel |
Starter series |
Stress and inflammation signaling research |
|
Protein Extraction & Detection Kits |
Absin series |
Sample preparation for phosphorylation analysis |
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights
